Oncolytic virotherapy is an effective cancer treatment that uses a special virus capable of finding and destroying malignant tumor cells in the body. Rigvir is the first registered virus and remains the only genetically unmodified virus available worldwide.
3 things about Rigvir® security that you probably didn’t know:
Weak side effects
Selective orientation
Can be combined with other treatments
OzonDenia is an accredited medical center in Spain for the practice of RIGVIR treatment.
RIGVIR® belongs to the group of drugs called immunomodulators. RIGVIR® is a virus-based immunomodulator with an antitumor response for the treatment of melanoma, local treatment of cutaneous and subcutaneous metastases of melanoma, for the prevention of relapses and metastases after radical surgery.
RIGVIR® is a live, non-pathogenic Picornaviridae, genus Enterovirus, ECHO group, type 7 virus that has not been genetically modified.
RIGVIR® has oncolytic and oncotropic properties, selectively infecting tumor cells. Oncolytic virotherapy with RIGVIR® is a safe and effective cancer treatment that improves time to progression, overall survival and quality of life for cancer patients. RIGVIR® is well tolerated and does not cause any serious adverse effects, if any.
RIGVIR® finds and infects tumor cells. This process is called oncotropism. Subsequently, RIGVIR® replicates in tumor cells and destroys them. This process is called oncolysis. Both processes, oncotropism and oncolysis, are selective for tumor cells and healthy cells are only minimally affected, if at all.
It is indicated for cancer therapy, prevention of recurrences and metastasis. As well as in the treatment of secondary immunodeficiencies. It is a good option for patients with resistance to chemotherapy and radiotherapy. The benefits of Rigvir administration have been demonstrated in the following types of cancer:
RIGVIR® is administered intramuscularly and should be stored at -20°C, transported frozen and thawed just prior to use.
RIGVIR® was first registered in Latvia in 2004. Currently, RIGVIR® is also approved in Georgia, Armenia and Uzbekistan, ensuring the drug’s availability in a market of approximately 40 million people. National registration processes have also been initiated in other countries.
Both pre- and post-registration studies have demonstrated significant RIGVIR® response to many types of cancer in addition to melanoma, e.g., stomach and rectal cancer, etc., as well as rare diagnoses.
Learn more in the clinical trials and results section of the page.
According to Acta Medica Lituanica, a medical journal (year 2002):
According to APMIS (Acta Pathologica, Microbiologica et Immunologica Scandinavica), a medical journal (July 2016):
“All patients started treatment with Rigvir a few months after diagnosis and are currently continuing treatment with Rigvir … With current standard treatments, survival for patients with current diagnoses is low. In contrast, the patients described here were diagnosed 3.5, 7.0 and 6.6 years ago, and their condition has improved and remained stable for more than 1.5, 6.5 and 4 years, respectively. These observations suggest that Rigvir virotherapy can be used successfully in the long-term treatment of patients with stage IV M1c melanoma, stage IIIA small cell lung cancer and stage IV histiocytic sarcoma…”.
These are the personal experiences of patients. This information is not medical advice. Health care specialists assume responsibility for the treatment of a patient based on their professionalism, experience and the information they have about a patient.
Start: 3 injections at the rate of one injection per day for 3 days in a row.
First year: 1 injection per month
According to year: 1 injection every two months
Third year: 1 injection every 3 months
Each injection costs 700 euros.